Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C when treated with peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy

被引：0
作者：
Marcellin, P
Lau, G
Piratvisuth, T
Luo, KX
Bonino, F
Thongasawat, S
Cooksley, G
Hadziyannis, S
Chutaputti, A
Lu, ZM
Fried, M
Chow, WC
Yurdaydin, C
Berg, T
Pluck, N
机构：
[1] Hop Beaujon, Clichy, France
[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Songklanakarin Hosp, Songkhla, Thailand
[4] Nangfang Hosp, Guangzhou, Peoples R China
[5] IRCCS Osped Maggiore, Sci Direct, Milan, Italy
[6] Chiang Mai Univ, Chiang Mai 50000, Thailand
[7] Univ Queensland, Royal Brisbane Hosp, Herston, Qld, Australia
[8] H Dynant Hosp, Athens, Greece
[9] Pramongkutklao Hosp, Bangkok, Thailand
[10] Ruijin Hosp, Shanghai, Peoples R China
[11] Univ N Carolina, Chapel Hill, NC USA
[12] Singapore Gen Hosp, Singapore 0316, Singapore
[13] Ankara Univ, TR-06100 Ankara, Turkey
[14] Charite Humboldt Univ Berlin, Berlin, Germany
[15] Roche, Welwyn Garden City, England
来源：
HEPATOLOGY | 2004年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：668A / 668A
页数：1
相关论文
共 50 条
[21]   Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin [J].
Snoeck, Eric ;
Wade, Janet R. ;
Duff, Frank ;
Lamb, Matthew ;
Jorga, Karin .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) :699-709
[22]   PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN [J].
Mauss, S. ;
Schober, A. ;
Lutz, T. ;
Moog, G. ;
Schuchmann, M. ;
Heyne, R. ;
John, C. ;
Schiffelholz, W. ;
Baumgarten, A. ;
Hey, K. -H. ;
Eisenbach, C. ;
Teuber, G. ;
Schmidt, W. ;
Bruch, H. -R. ;
Geyer, P. ;
Alshuth, U. ;
Hueppe, D. .
JOURNAL OF HEPATOLOGY, 2011, 54 :S185-S185
[23]   Predictive Factors of Thrombocytopenia in Treatment of Chronic Hepatitis C (CHC) Patients With Peginterferon Alfa-2a (40KD) and Ribavirin [J].
Mauss, Stefan ;
Schober, Andreas ;
Lutz, Thomas ;
Moog, Gero ;
Schuchmann, Marcus ;
Heyne, Renate ;
John, Christine ;
Schiffelholz, Willibold ;
Baumgarten, Axel ;
Hey, Karl-Heinz ;
Eisenbach, Christoph ;
Teuber, Gerlinde ;
Schmidt, Wolfgang ;
Bruch, Harald-Robert ;
Geyer, Peter ;
Alshuth, Ulrich ;
Hueppe, Dietrich .
GASTROENTEROLOGY, 2011, 140 (05) :S948-S948
[24]   Peginterferon alfa-2a (40KD) (PEGASYS®) in combination with ribavirin in African American and Caucasian patients with chronic hepatitis CHCV genotype 1:: Safety and tolerability. [J].
Howell, C ;
Jeffers, LS ;
Cassidy, W ;
Reddy, R ;
Sheridan, S ;
Ho, I ;
Khouri, S ;
Harb, G .
HEPATOLOGY, 2003, 38 (04) :319A-319A
[25]   Cost-effectiveness of peginterferon alfa-2a (40KD) for the treatment of chronic Hepatitis B in Italy [J].
Eandi, M. ;
Iannazzo, S. ;
Pradelli, L. ;
Patel, K. ;
Giuliani, G. .
VALUE IN HEALTH, 2006, 9 (06) :A301-A302
[26]   Response to peginterferon alfa-2a (40KD) (PEGASYS) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B [J].
Cooksley, Graham ;
Lau, George ;
Marcellin, Patrick ;
Piratvisuth, Teerha ;
Lai, Ming-Yang ;
Bonino, Ferruccio .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 :A32-A32
[27]   Treatment of chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV) in patients older than 60 years [J].
Meyer, Ulrike ;
Zehnter, Elmar ;
Mauss, Stefan ;
Boeker, Klaus ;
Lutz, Thomas ;
Racky, Stefan ;
Schmidt, Wolfgang ;
Ullrich, Rainer ;
Sbrijer, Innessa ;
Heyne, Renate ;
Schober, Andreas ;
John, Christine ;
Hey, Karl-Heinz ;
Bokemeyer, Bernd ;
Kallinowski, Birgit ;
Moeller, Bernd ;
Pape, Stefan ;
Alshuth, Ulrich ;
Hueppe, Dietrich .
GASTROENTEROLOGY, 2007, 132 (04) :A790-A791
[28]   Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study [J].
Wirth, Stefan ;
Zhang, Hongfei ;
Hardikar, Winita ;
Schwarz, Kathleen B. ;
Sokal, Etienne ;
Yang, Weibo ;
Fan, Huimin ;
Morozov, Vyacheslav ;
Mao, Qing ;
Deng, Hong ;
Huang, Yang ;
Yang, Lei ;
Frey, Nicolas ;
Nasmyth-Miller, Clare ;
Pavlovic, Vedran ;
Wat, Cynthia .
HEPATOLOGY, 2018, 68 (05) :1681-1694
[29]   Peginterferon alfa-2a in patients with chronic hepatitis C [J].
Zeuzem, S ;
Feinman, SV ;
Rasenack, J ;
Heathcote, EJ ;
Lai, MY ;
Gane, E ;
O'Grady, J ;
Reichen, J ;
Diago, M ;
Lin, A ;
Hoffman, J ;
Brunda, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23) :1666-1672
[30]   The cost effectiveness analysis of treatment with peginterferon alfa-2a (40KD) in patients with hbeag-negative chronic hepatitis B [J].
Kowalik, E. ;
Niewada, M. ;
Jakubczyk, M. ;
Horban, A. ;
Berak, H. ;
Szkultecka-Debek, M. .
VALUE IN HEALTH, 2006, 9 (06) :A300-A300
12345